Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,713.41
+16.790.62%
Number of Gainers:61
Number of Losers:36
Number of Flat:1
PE:- -
High:2,716.75
Open:2,697.09
Low:2,696.99
Close:2,696.62
Volume:968.55M
Turnover:196.35B
Market Cap:49.63T
Float Cap:46.17T

Loading ...

Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone

TIPRANKS
·
Oct 03

Cboe data shows mixed options sentiment in Alphabet with shares up 1.53%

TIPRANKS
·
Oct 03

Nike Is Still Searching for Its Turnaround As Wall Street Sees Another Tough Year

Benzinga Earnings
·
Oct 03

Taiwan Semiconductor Manufacturing Co Ltd Stock (TSM) Moved Up by 3.16% on Oct 2: A Full Analysis

TradingKey
·
Oct 03

Accenture PLC Stock (ACN) Moved Down by 4.67% on Oct 2: Key Drivers Unveiled

TradingKey
·
Oct 03

Top Midday Stories: Nvidia Adds Local AI Options; Nike's Weak Fiscal 2027 Outlook; Paramount Skydance to Change Name

MT Newswires Live
·
Oct 03

Nike Stock Considered at Risk of Further Declines

Dow Jones
·
Oct 03

United Parcel Service Likely to Deliver In-Line Results, UBS Says

MT Newswires Live
·
Oct 02

Google Cloud: Announces General Availability of Spanner Queues for Transactional Messaging in AI Agent Workloads - Blog

THOMSON REUTERS
·
Oct 02

Nvidia Stock (NVDA) Hits All-Time High Days After Announcing Record Buyback

TIPRANKS
·
Oct 02

Nike's Right-Sizing Efforts are Dragging

Dow Jones
·
Oct 02

Amazon and Microsoft Cloud Businesses Could Face Tougher EU Rules as Soon as November

TIPRANKS
·
Oct 02

Update: BofA Securities Adjusts Nike Price Target to $24 From $30, Maintains Underperform Rating

MT Newswires Live
·
Oct 02

NVIDIA Launches 64GB DGX Spark With Halved Memory Starting at $4,999, While 128GB Version Jumps to $6,950

Deep News
·
Oct 02

Expeditors International of Washington Seen Benefiting From Stronger Ocean Rates, Airfreight Growth, UBS Says

MT Newswires Live
·
Oct 02

Can Google's New Flagship Model Finally Match OpenAI and Anthropic at the Frontier?

Deep News
·
Oct 02

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02